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Dynamic (latent or/and labile) obstruction of left ventricular outflow (LVOT) was recognized from the earliest clinical descriptions
of hypertrophic cardiomyopathy (HCM) and has proved to be a complex phenomenon, as well as arguably the most audible
(“visible”) pathophysiological hallmark of this heterogeneous disease.The aimof the current review is focused on two novel issues in
a subgroup of obstructiveHCM. Firstly, the importantmethodological problem inHCMis the examination of a subgroup of patients
with nonobstructive hypertrophy in resting conditions and hard, but possible provoking obstruction. Recently, investigators have
proposed physiological stress test (with double combined stimuli) to disclose such type of patients.The upright exercise is described
in the ESC guideline on hypertrophic cardiomyopathy from 2014 and may appear as a candidate for gold standard provocation
test. The second novel area of interest is associated with elevated level of signaling biomarkers: hypercoagulation, hemolysis,
acquired von Willebrand 2A disease, and enhanced oxidative stress. The accelerated and turbulent flow within narrow LVOT may
be responsible for these biochemical disturbances. The most recent advances in the treatment of obstructive HCM are related to
nonpharmacological methods of LVOT gradient reduction. This report extensively discusses novel methods.
1. Introduction
History of recognition of hypertrophic cardiomyopathy
(HCM) and definition of frequency of obstructive form is
associated also with methodology of stress test to provoke
LVOT gradient >30mmHg. Maximized and (semi)physio-
logical stress tests were introduced only several years ago.
For more than 50 years, in the period of first description
among alive patients (in preechocardiographic era, Figure 1),
HCM was only exclusive as obstruction, where systolic
murmur in auscultation was verified as turbulent flow with
gradient in obstructive LVOT measured invasively [1–3]. In
fact, in the early preechocardiographic era (1957 to 1969), an
outflow gradient was a virtual prerequisite for the diagnosis
ofHCM.Dynamic obstruction to LVOT rapidly achieved dis-
tinction as themost represented feature of HCM, dominating
the initial comprehensive description of the disease.
Thus, predominantly, but not solely [4, 5], obstructive
HCMhas been diagnosed in early reports. After introduction
of echocardiography [6–8] (Figure 1), during family screening
for sudden cardiac death, a large number of nonobstructive
patients were recognized. In this period researchers postu-
lated that, in the whole population of HCM, the ratio of
the obstructive: nonobstructive is 1/3 : 2/3. In 2003 it was
reported that, among older patients, female’s left ventricular
contractility was higher and LVOT gradient occurred more
frequently than in males [9]. Recent observation that the
vast majority of patients with HCM have the propensity to
develop outflow obstruction (either at rest or with exercise)
underscores a return to the characterization of HCM in early
period of exploration as a predominantly obstructive disease
[10].
To sum up the history, our perception of obstruct-
ive : nonobstructive ratio has changed during the last 55 years.
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Figure 1: Probable timeline displaying major events concerning the
history of left ventricular outflow tract obstruction in hypertrophic
cardiomyopathy. Point 1: first description of obstructive HCM by
Brock. Point 2: Morrow and Braunwald (1959) and Braunwald et
al. (1960): all patients were defined as obstructive HCM by systolic
murmur in auscultation and LVOT gradient in invasive catheter-
ization. Point 3: Braunwald et al. (1962, 1963), description of first
HCM patient without obstruction. Point 4: first echocardiographic
image of SAM by Shah et al. Point 5: echocardiographic description
of asymmetrical left ventricular hypertrophy by Henry et al. Point 6:
description of using ofDDDpacing. Point 7: description of interven-
tion defined as alcohol septal ablation. Point 8: publication byMaron
et al. describing exercise test for LVOT gradient provocation.
In Figure 1 we can recognize early period of obstructive
predominance, midperiod with nonobstructive advantage
due to broad availability of echocardiography, and later
period with increasing frequency of obstructive form up to
value 70% [10]. The low percent of obstruction proportions
started to reverse during the nineties. With the introduction
of less invasive than myotomy-myectomy, but nonpharma-
cological therapies, DDD pacing [11] and alcohol septal
ablation [12] were associated with more selected groups of
patients (referral bias) and increasing types and numbers of
provocative maneuvers. More varied stimuli were needed to
more adequately qualify patients with obstruction.
2. History of LVOT Provoking Stimuli
Obstruction in HCM has been featured by dynamic nature
[13, 14], in which pressure gradients can vary considerably
with a variety (nonstandardized methodology) of pharma-
cological and physiological provocations that reduce periph-
eral arterial pressure or ventricular volume or enhance
myocardial contractility and may change even after heavy
meals or alcohol intake or spontaneously on a day-to-day
or hour-to-hour basis [10, 13–21]. Mechanisms predisposing
to LVOT gradient induction are presented in Figure 2. It
was recognized that dynamic outflow gradients could be
provoked by physiological exercise or a variety of nonphysio-
logical maneuvers, including sympathomimetic agents, such
as infused isoproterenol or dobutamine, or by introducing
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Figure 2: Mechanisms predisposing to LVOTG induction. A: left
ventricular hypertrophy, particularly basal septal segment (HCM,
hypertension, and storage disease). B: LV hypercontractility (mod-
erate tachycardia). C: small size LV cavity (HCM, children, women,
dehydration). D: prolonged/thickened mitral leaflet(s). E: reduced
LV preload (dehydration, diuretics, vasodilators, hemodialysis,
fever, and septic shock).
premature ventricular beats, amyl nitrite inhalation or nitro-
glycerin, and the Valsalva maneuver [10, 13–21]. The ground
breaking point occurred in 2006, whenMaron et al. proposed
exercise as a provocation and therefore the obstructive group
was as numerous as 70% [10].
Importantly, this study included a large number of
patients. However, there are some disadvantages of the
proposed method. The gradient provoked by exercised stress
test was measured with delay in postexercise recovery and
in semisupine position, instead of at peak exercise in upright
position.
Earlier, in small selected group of patients, German [22]
and Portuguese [23] investigators proposed pioneering full-
upright exercise test. Researchers began to consider that we
need natural, strong but physiological stimuli. The exercise
test to provoke gradient has been postulated as a gold
standard.Thus, the latest step of development was to combine
two (perfectly physiological) stimuli, that is, upright position
(reduced LV preload) and exercise by ergometer or treadmill
[18, 20–31] (Figure 3). Standing position, both at rest and
during exercise, is a normal and fundamental activity of
daily life but may precipitate an unexpected fall in cardiac
patients predisposed to syncope, especially in patients with
unsuspected LVOT obstruction. Recently, a novel interesting
combination was use of exercise test with postprandial status
which additionally reduces LV preload [32].
In the most recent report, other types of stimuli have
been combined—nitroglycerine and Valsalva to maximize
provocation [33]. Proposed procedure is less time-consuming
and does not require special equipment [33]. Looking for
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Figure 3: Intraventricular gradient present in all phases of the study
in a HCM patient with increase also after exercise in orthostatic
position.
new clinical applications, it has been proposed to use exer-
cise stress echocardiography in the upright position with
LVOT gradient monitoring both during and after exercise,
as a marker of genotype-positive/phenotype negative hyper-
trophic cardiomyopathy (prehypertrophic status of HCM)
[34]. Upright exercise to provoke (sub)valvular gradient has
been used in many cardiac diseases [18].
3. Turbulent Flow and Activated
Various Biomarkers
Apart from hemodynamic disturbances, obstructive HCM
may induce several hematological abnormalities. Abnormal-
ities in blood parameters associated with hemolysis and
hypercoagulability status have been recently recognized.
Accordingly, in two Japanese articles [35, 36], the interest-
ing biochemical phenomenon of hemolysis in hypertrophic
cardiomyopathy (HCM) patients has been clearly docu-
mented, concerning only patients with the obstructive form.
In the first case report [35], mechanical intracardiac hemol-
ysis due to LVOT obstruction was advanced and hemolytic
anemia recurred. Implanted DDD pacing decreased the
LVOT gradient and reduced hemolysis. In the next article,
stabile and provoked obstruction was associated with hemol-
ysis [36]. Importantly, for everyday practice, this hemolysis
appears to be associated also with LVOT obstruction, only
provoked by daily physical activities. Although there was
no relation between erythrocyte creatine levels and LVOT
gradient in the subgroup of patients without obstruction
at rest (before provoked stress test), a correlation between
erythrocyte creatine and LVOT gradient provoked by Val-
salva became significant in the subgroup of nonobstructive
patients. Summing up, patients with higher erythrocyte
creatine levels exhibited greater LVOT gradient with Valsalva
provocation.
These results suggest that intravascular hemolysis is
correlated with severity of LVOT obstruction not at rest, but
with daily activities. Importantly, as a clinical implication, this
biomarker may be useful for the identification of a subgroup
of HCM patients with latent (none easily identified) obstruc-
tion. In perspective, we may postulate that measurement of
this biomarker appears to be valuable for monitoring and
management of HCM with not only stable, but especially
interesting labile obstruction.
Hematological abnormalities were described in other
studies, which clearly documented increased levels of
biomarkers heralding hypercoagulation [37]. Moreover,
acquired type of von Willebrand disease (type 2A) [38] has
been recognized. It was postulated that rapidly turbulent
blood flow within LVOT (narrow, irregular canal) obstruc-
tion plays a stimulating role in the activation of various
biomarkers and hematological processes.
LVOT obstruction in HCM may provoke procoagulant
mechanisms due to high shear stress. Both anatomical
(systolic anterior motion of mitral leaflet with or without
septal contact) and hemodynamical (high pressure gradient)
abnormalities generating turbulent flow might play a role
in the prothrombotic state [37]. The precise role of long
and thickened mitral leaflets disturbing flow to nonlaminar
pattern is an important question for further exploration of
hematological disturbances.
Next, pathology in obstructive HCM [38] is the evidence
of von Willebrand factor (vWF) impairment as frequent
deficiency and closely related to the magnitude of LVOT
obstruction. The problem is large in scale because resting
LVOT gradient as low as 15mmHg (common definition of
obstruction is >30mmHg) is absolutely sufficient to impair
vWF. The proposed [38] interpretation of hemodynamic-
hematologic phenomenon is attractive. Given the unique
shear stress characteristics of vWF, it has been postulated
that accelerated LVOT velocity at rest or during exercise
might increase proteolysis of vWF multimers and impair
primary hemostasis in the obstructive HCM. The biological
effect of LVOT obstruction on vWF function is detectable
in patients with either baseline or latent (exercise-provoked)
obstruction. Primary hemostasis assays that assess vWF func-
tion impairment strongly correlate with the maximal LVOT
gradient and improve with therapeutic intervention reducing
gradient. Hemostasis impairment might be responsible for
spontaneous bleeding in patients with an obstructive form of
HCM.
In conclusion, the authors [38] have demonstrated that
high shear forces could induce structural changes in the shape
of the vWF molecule, facilitating the action of the specific
vWF protease ADAMTS 13, which would lead to the loss
of the high-molecular-weight multimer of vWF. Importantly,
this process may be reversed by alcohol septal ablation [39]
and septal myectomy [40] reducing LVOT gradient.Thus, we
are able to correct hematological abnormalities by reduction
of LVOT obstruction. In gastrointestinal bleeding as com-
plication of Heyde’s syndrome, thalidomide and octreotide
therapy can be used to bridge to surgical or alcohol septal
ablation [41].
According to other biochemical abnormalities, enhanced
oxidative stress [42] and endothelial dysfunction [43] are also
characteristics features for obstructive HCM.
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4. Role of High Troponin
As regards biomarker of ischemic injury of myocardium,
levels of serum cTnI are elevated in a significant proportion
of obstructive HCM patients [44]. Serum cTnI is associated
with multiple parameters of disease severity, suggesting its
great significance in assessing cardiac remodeling in patients
with obstructive HCM. In obstructive HCM left ventricular
hypertrophy is the major determinant of serum cTnI levels
[44] and high level of serum cTnT is associated with the
presence of AF [45].
Serum cTnI is an independent predictor useful for iden-
tifying myocardial fibrosis visualized by late hyperenhance-
ment of gadolinium in cardiac magnetic resonance [46].
5. Pharmacological Treatment:
Negative Inotropic Effect
According to eminent expert Sherrid [47], inotropic neg-
ative effectiveness (power) is categorized as follows: beta-
blocker > disopyramide > verapamil. Disopyramide pos-
sesses additional beneficial value, that is, vagolytic effect,
acting as antibradycardia agent. This positive chronotropic
effect of disopyramide may beneficially counterbalance the
negative chronotropic effect of beta-blocker and together
provide opportunity to safety combination of both drugs
for aggressive, but only pharmacological reduction of LVOT
gradient.
6. Nonpharmacological Option for Treatment
Generally, two invasive methods are strong competitors in
current armamentarium. The comparison between surgical
myotomy-myectomy and alcohol septal ablation (ASA) is
most interesting, whereas DDD pacing is marginalized for
rare indication. However in Spanish center [48] beneficial
effect has been observed in 18-year-long follow-up study on
DDD pacing. Sequential pacing in selected patients with
obstructive HCM improves functional class and reduces
dynamic gradient and mitral regurgitation immediately after
pacemaker implantation and at final follow-up [48]. Pro-
longed ventricular pacing has no negative effects on systolic
or diastolic function in these patients. Both surgical and
transcoronary methods have dynamically developed. The
long-term survival and clinical outcome of the ASA and
surgical method are extensively debated in both USA and
Europe. The crucial problem is safety of both invasive meth-
ods. Very recently, an important document has appeared [49],
analyzing systematic review and meta-analysis of long-term
outcomes after invasive septal reduction intervention therapy
in obstructive HCM. In large-scale analysis, the authors
have compared sixteen cohorts, including 2791 patients after
myectomy (mean follow-up: 7.4 years) versus 11 ASA cohorts
with 2013 patients (mean follow-up: 6.2 years). Importantly,
long-term mortality and (aborted) SCD rates after ASA and
myectomy are similar and importantly low. Patients who
undergo ASA have more than twice the risk of perma-
nent pacemaker implantation and 5 times higher risk of
the need for additional septal reduction therapy, compared
to those who undergo myectomy. Also, other systematic
analysis [50] confirmed no significant difference in symptom
relief between the two approaches. ASA was as safe as
myectomy with regard to SCD and short-term and long-
term mortality. The benefit from ASA has been very recently
confirmed by Veselka et al. [51] studies, suggesting that, in
patients with obstructive HCM and important symptoms
who underwent ASA, long-term survival after the procedure
did not differ significantly from that of the general popula-
tion. Additionally, Veselka et al. [52] have documented that
results of the first European multicenter study demonstrated
that real-world early outcomes of ASA patients were better
than had been reported in earlier observations from the first
decade after ASA introduction. Finally, in the newest, large-
scale multinational Euro-ASA registry with 1275 patients,
Veselka et al. [53] have demonstrated low periprocedural and
long-term mortality after ASA. This intervention provided
significant relief of symptoms and a reduction of LVOT
obstruction.
TheAmerican College of Cardiology Foundation/Ameri-
can Heart Association guidelines reserve ASA for elderly
patients and patients with serious comorbidities but recent
study [54] changes the clinical perspective. Accordingly,
ASA is similarly effective for reduction of symptoms in
young and elderly patients; however, younger patients have
a lower risk of procedure-related atrioventricular conduction
disturbances.The long-termmortality rate and risk of adverse
arrhythmic events following ASA are low, in both young
and elderly patients, and are comparable to age-matched
nonobstructive HCM patients.
From pathophysiological point of view, LVOT obstruc-
tion and subsequent mitral regurgitation appear to further
impair left atrial functional mechanics [55]. Importantly,
septal myectomy has significantly reduced left atrial volumes,
paralleled by an improvement in hemodynamic function
[55].
7. From Technical Point of View in
Both Surgical and ASA Procedures Novel
Invasive Interventions Have Been Very
Recently Developed
Myectomy cannot be performed in 5–15%, due to technical
difficulties. Also ASA methodology has several limitations,
which are currently overcome. The newest 10 innovative
procedures have been discussed.
7.1. 1st Innovation. Modification of surgical approach: expo-
sure of the basal and midventricular septum through the
aortic root to relieve obstruction in HCM can be challenging.
Inadequate myectomy will lead to persistent symptoms and
disability. Adequate exposure of the obstructive left ventric-
ular septum is of paramount importance in primary and
secondary corrected myectomy. In selected patients, either
at primary myectomy or at remyectomy, septal excision can
be approached through a left ventricular transapical incision
when transaortic exposure is inadequate [56]. Transapical
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Figure 4: Cardiac magnetic resonance imaging before and after septal reduction therapy (myocardial scar after blockage of septal perforator
artery by coil). Example of extension of delayed contrast-enhanced images of patchy areas of hyperenhancedmyocardial in the interventricular
septum 7 days (b, e) and 3 months (c, f) when compared with baseline (a, d). (a–c) Shot axis view. (d–f)Three-chamber view (reprinted with
permission from [65]).
myectomy may be suitable approach for severe midventric-
ular obstructive HCM [57].
7.2. 2nd Innovation. In surgical approach a very novel inter-
vention is transaortic chordal cutting with mitral valve repair
for obstructive HCMwith mild septal hypertrophy [58].This
procedure relieves heart failure symptoms, abolishes LVOT
gradient, and avoidsmitral valve replacement in patients with
obstructive HCM and mild septal thickness.
7.3. 3rd Innovation. There is strong evidence that treating
the mitral valve abnormalities is a key feature of obstructive
HCM. Investigators [59] successfully corrected both the
anterior andposterior leaflet size and geometry.Theproposed
technique is double-stage procedure: first septal resection
through the aortic valve and the detached anterior leaflet of
the mitral valve and second mitral valve repair by reducing
posterior leaflet height (leaflet resection or artificial neochor-
dae) and increasing anterior leaflet height with pericardial
patch.
7.4. 4th Innovation. The new concept has been also devel-
oped on percutaneous technique [60–62]. It was reported
on catheter-based treatment of LVOT obstruction, targeting
primarily a systolic anterior motion of the anterior mitral
leaflet in obstructive HOCM. A patient was successfully
treated with the MitraClip [60] two years after septal myec-
tomy, in conjunction with mitral valve repair. The results
prove the concept that systolic anterior motion (SAM) is
clearly involved in gradient formation and is more than an
epiphenomenon in obstructive HCM. Thus, SAM-induced
subaortic obstructionmight be a target forMitraClip implan-
tation.
7.5. 5th Innovation. The transradial approach using a sheath-
less guiding catheter has appeared feasible and safe for ASA
[63].
7.6. 6th Innovation. Peri-intervention monitoring of labile
LVOT gradient is very practical. The intravenous nitroglyc-
erin test during ASA is a useful method for rapidly con-
firming acute reduction of the latent gradient after the ASA
procedure, and the outcome of ASA for labile obstructionwas
favorable [64].
7.7. 7th Innovation. It consists in nonsurgical septal myocar-
dial reduction (ischemic scar by coil embolization into septal
perforator artery) [65] (Figure 4).
7.8. 8th Innovation. Glue septal ablation is a promising tech-
nique for the reducing LVOT obstruction [66]. Glue seems
to be superior to alcohol due to some intrinsic advantageous
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properties of glue such as immediate polymerization which
prevents the leak into the left anterior descending coronary
artery. Glue septal ablation technique is particularly useful in
patients with collaterals to the right coronary artery in whom
alcohol ablation is risky and contraindicated.
7.9. 9th Innovation. Improved renal function in a patient
with obstructive HCM after multidetector computed tomog-
raphy-guided ASA was witnessed [67].
7.10. 10th Innovation. Cooper et al. [68] have proposed that
method of delivering percutaneous tissue damage to the
septum that is not reliant on coronary anatomy is desirable.
To directly ablate the interventricular septum at the mitral
valve systolic, anterior motion-septal contact point using
radiofrequency energy guided by CARTOSound was shown.
The authors have postulated that radiofrequency ablation
using CARTOSound guidance is accurate and effective in
treating LVOT gradients in HCM.
8. Phenocopies with LVOT Gradient with
Successful ASA Treatment
Useful for everyday practice are reports of invasive reduction
of LVOT gradient in diseases mimicking HCM as pheno-
copies.This problem is associatedwith storage and infiltrative
disease. Using ASA method, LVOT gradient was effectively
reduced in Fabry disease [69] and amyloidosis [70]. Surgical
correction was successfully performed in Noonan disease
[71]. Septal myectomy may be a viable option to relieve
symptoms and interrupt progression of heart disease also in
selected Friedreich’s ataxia patients [72].
9. Conclusion
From a practical point of view, the effective monitoring,
including biochemical biomarkers indicating reduction of
LVOT gradient, is important because this parameter has
become a risk factor for sudden death in the 2014 ESC guide-
line [73]. In this context, the maximized physiological LVOT
gradient provocation stimulus seems to be an important diag-
nostic element. Novel invasive therapeutic techniques have
been recently dynamically developed, providing attractive
treatment opportunities.
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